Teva Pharmaceutical (NYSE:TEVA) shares rise 3.4% premarket as surpassed analyst expectations.

梯瓦制药股价在盘前上涨3.4%，涨幅超过分析师预期。

Revenues were $4,454M, flat compared to Q4 2019.

营收为44.54亿美元，与2019年第四季度持平。

Key product sales (North America): Generics: $1,206M (+6%), boosted by the successful launch of the generic HIV-1 treatments Truvada and Atripla tablets in U.S.

主要产品销售额(北美):仿制药:12.06亿美元(+6%)，主要得益于美国仿制HIV-1药物特鲁瓦达(Truvada)和阿特里普拉(Atripla)的成功上市

Anda: $321M (-22%); Copaxone: $213M (-19%); Austedo: $185M (+36%); Bendeka/Treanda: $102M (-19%); Ajovy: $36M (+42%).

安达:321美元(-22%);Copaxone: 213美元(-19%);Austedo: 185美元(+ 36%);Bendeka / Treanda: 102美元(-19%);Ajovy: 36美元(+ 42%)。

"Our key growth drivers delivered promising results and milestones, including the continued growth of AUSTEDO and our leading biosimilar TRUXIMA, as AJOVY sales continued to improve following the launch of the auto-injector," said Mr. Kåre Schultz, President and CEO.

“我们的关键增长驱动力交付了有希望的结果和里程碑，包括AUSTEDO和我们领先的生物仿制药TRUXIMA的持续增长，因为AJOVY的销售在自动注入器推出后继续改善，”Kåre Schultz先生说，总裁兼首席执行官。

Non-GAAP gross profit margin of 52.3%, compared to 50.6% in Q4 2019.

非gaap毛利率为52.3%，低于2019年第四季度的50.6%。

Net income: $150M (+36.4%); EPS: $0.14 (+40.0%); non-GAAP net income: $753M (+10.2); non-GAAP EPS: $0.68 (+9.7%).

净收入:1.5亿美元(增长36.4%);每股收益:0.14美元(+ 40.0%);非公认会计准则净利润:7.53亿美元(+10.2);非公认会计准则每股收益:0.68美元(+9.7%)。

Cash flow ops (3 months): $331M (-38.5%).

现金流量(3个月):3.31亿美元(-38.5%)。

2021 guidance: Revenue: $16.4B - 16.8B (consensus $16.77B); non-GAAP EPS: $2.50 - 2.70 ($2.63 consensus); EBITDA: $4.8B - 5.1B; FCF: $2.0B - 2.3B.

2021年指导意见:收入:164亿- 168亿美元(共识为167.7亿美元);非公认会计准则每股收益:2.50 - 2.70美元(共识为2.63美元);EBITDA: 48亿- 51亿美元;FCF: 20亿- 23亿美元。

Previously (Feb. 10): Teva Pharmaceutical EPS beats by $0.06, beats on revenue

前情回顾(2月10日):梯瓦制药EPS比营收高出0.06美元